Navigation Links
Elsevier Launches Publishing Ethics Resource Kit
Date:3/4/2008

AMSTERDAM, March 4 /PRNewswire-FirstCall/ --

- Online Resource to Support Journal Editors Handling Publishing Ethics Issues

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, announced today the launch of its Publishing Ethics Resource Kit (PERK) (http://www.elsevier.com/publishingethicskit).

Launching PERK at the Elsevier Editors' Conference in Singapore, Mark Seeley, Senior Vice President and General Legal Counsel, described PERK as being "a single point of access for information and guidelines on publishing ethics providing our Journal Editors with the support they need in dealing with issues of publishing ethics."

PERK is an online resource which contains links to Elsevier and non-Elsevier policy and procedures documents, decision trees and flow charts for dealing with different forms of publishing ethics abuse with the recommended action that can be followed, as well as COPE (Committee On Publication Ethics, http://www.publicationethics.org.uk/) charts for a second opinion. It also contains examples of appropriate letters for various situations and a large resource of useful information structured in the form of Questions and Answers.

As part of our commitment to the protection and enhancement of the peer-review process, we have a responsibility to assist the scientific community in all aspects of publishing ethics" says Martin Tanke, Managing Director S&T Journal Publishing. "In the past months we have been the first major scientific publisher to commit to full membership for all its publications in COPE and we are one of six scientific publishers participating in the CrossRef Association's pilot plagiarism software called CrossCheck (http://www.elsevier.com/ed
'/>"/>

SOURCE Elsevier
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Elsevier launches new journal: Stem Cell Research
2. Elsevier announces new journal on inflammatory bowel diseases
3. Roy Jakobs Appointed Elsevier Managing Director, A&G Sales and Customer Marketing
4. Excerpta Medica and Elsevier Interactive Solutions merge into 1 integrated provider
5. Elsevier journals participate widely in global theme issue on poverty and human development
6. ScienceDirect to host French-language journals from Elsevier Masson
7. Elseviers "WiserWiki" Allows Physicians to Update Evidence-Based Medical Information With Experience-Based Practice Insights
8. Elseviers WiserWiki allows physicians to update evidence-based medical information
9. Elsevier Foundation Announces Grants for Innovative Libraries and New Scholars
10. Elsevier Foundation announces grants for innovative libraries and new scholars
11. Elsevier enhances clinical decision making with suite of Clinical Decision Support solutions
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6COMFORCE Corporation to Hold Conference Call to Discuss Second Quarter 2009 Results 53484 1COMFORCE Corporation to Hold Conference Call to Discuss Second Quarter 2009 Results 53484 2Therapy Technique Cuts Divorce Separation Rate By Nearly 50 Percent 53482 1Therapy Technique Cuts Divorce Separation Rate By Nearly 50 Percent 53482 2Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 1Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 2Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 3Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 4